Galenicum, exhibitor at CPhI 2021

galenicum_cphi2021_06_009-20211029145747-20211108150734.jpg

November, 2021

Visit us AT CPhI Worldwide 2021

From November 9th until November 11th Galenicum will be exhibiting at the CPhI worldwide 2021. This will be the first event since the COVID-19 pandemic that the whole Galenicum team will be attending.

For the first time since 2019, we have the possibility to reconnect and meet in person in one of the most important pharma trade fairs worldwide. For this reason, we are keeping the tradition of being an exhibitor, and we take the opportunity to receive all our customers and suppliers at our booth. If you are not yet a partner or you have not scheduled an appointment, come visit us at our stand at Hall 1, number 1F31 in the Feria Milano.

Cphi is the major event of the pharma industry. It unites thousands of pharma suppliers and buyers worldwide under the same roof, and it is one of the best platforms to connect with different stakeholders of the industry.

If you are interested in in-licensing opportunities, Galenicum Axium will offer you a broad range of products from different therapeutic areas. We are looking for customers to license our already developed or under development dossiers so that we can supply these products in the commercial phase worldwide. Galenicum has commercial presence in more than 50 countries worldwide with more than 150 customers, and we are keen and ready to develop more.

If you are an API manufacturer, Galenicum Axium is also your partner. We have a team specialised in API, servicing local manufacturers in Spain and Portugal with API solutions from leading manufacturers. We are also interested in suppliers of APIs to develop our future dossiers and products.

If this appeals to you, please contact us to discuss all possible business opportunities during the conference. Our team will be ready and keen to receive you. 

Thanks for reaching out. We will get back to you as soon as possible.

RESTRICTED ACCESS

The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.

The products mentioned may have a different authorized data sheet in each country.

If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.

DABIGAMAX

DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.